FORM PTO-1390 MODIFIED		1380	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEWARK OUNTED		NUMBER 1487-28	
			nsmittal lette	r to the united states	U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5)	
				ted office (do/eo/us)		
Concerning a filing under 35 U.S.C. 371						
INTERNATIONAL APPLICATION NO.				INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED 1 August 2003	
PCT/FR2004/002050 30 July 2004 1 August 2003						
title of invention Novel anti-angiogenic agent and its use, in particular within the Framework of the treatment of Cancer						
APPLICANT(S) FOR DO/EO/US PLOUÊT SE SI.						
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:						
1,						
2.	120	This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.				
3.		This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include				
3.	Ц	items (5), (6), (9) and (21) indicated below.				
4.		The U.S. has been elected (Article 31).				
5.	A co	py of th	e International Applic	ation as filed (35 U.S.C. 371(c)(2).		
	8.	☐ is	s attached hareto (pages specification, claims & abstract (claims), sheets drawings).	
	b.		as been communicat	ed by the International Bureau.		
	C.	is not required, as the application was filed in the United States Receiving Office (RO/US).				
6.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(3))				
	a. Cert	is attached hereto (pages specification, claims & abstract (claims), sheets drawings, pagertificate of Translation).				
	b.		as been previously s	ubmitted under 35 U.S.C. 154(d)(4).		
7.		Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)				
	a .	are attached hereto (required only if not communicated by the International Bureau).				
	b.		ave been communica	ated by the International Bureau.		
	C.		ave not been made; l	however, the time limit for making such ame	endments has MOT expired.	
	d.		ave not been made a	nd will not be made.		
8.		An En	glish language transla	tion of the amendments to the claims under	r PCT Article 19 (35 U.S.C. 371(c)(3).	
9.	a.	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4).				
	b. Form	Declaration was submitted to the International Bureau during International Phase (see copies of Declaration (page m PCT/RO/101 and Form PCT/IB/371 and first page of printed publication acknowledging receipt thereof attached).				
10.						
U.S.C. 371(c)(5). Items 11 To 20 below concern document(s) or information included:						
11.				statement under 37 C.F.R. 1.97 and 1.98.		
12.		An ass	sianment document fo	or recording. A separate cover sheet in com	pliance with 37 C.F.R. 3.28 and 3.31 is included.	
13.	<u> </u>	_	FIRST preliminary a	•		
	b.	_		QUENT preliminary amendment.		
14.		An Application Data Sheet under 37 C.F.R. § 1.78.				
15.		A substitute specification.				
16.		A change of power of attorney and/or address letter.				
17.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.				
18.		A second copy of the published international application under 35 U.S.C. 154(d)(4).				
		A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).				

Other items or information. Copy of Notification of Missing Requirements